MSCs vs. MUSE Cells at a Glance
Category
MSCs (Mesenchymal Stem Cells)
MSCs (Mesenchymal Stem Cells)
Discovery
1960s–1970s, extensively studied
2010, relatively new discovery
Placenta, Wharton’s jelly, adipose, endometrium, dental pulp (abundant, scalable) Isolated directly, no reprogramming required Decades of global use; tens of thousands of patients; strong safety data 80,000+ papers, 1,500+ clinical trials
Rare subpopulation of MSCs (~1–3%)
Source
Enriched via stress-based selection methods
Preparation
Preclinical and early human trials suggest non-tumorigenic, but limited patient data
Safety Profile
<600 papers, <10 clinical trials
Evidence Base
Multiple approved products worldwide (e.g., Japan, South Korea)
Regulatory Use
No regulatory approvals to date
Arthritis, orthopedic repair, autoimmune, systemic inflammation, anti-aging Readily available, consistent, scalable
Stroke, heart attack, ALS, spinal cord injury (early-stage)
Clinical Focus
Rare, costly to manufacture, low yield
Practicality
Safe, proven, and effective for broad patient needs
Promising but experimental; not yet ready for routine use
Status Today
Longevity Medical Institute (C) Copyright. All Rights Reserved.
09
Made with FlippingBook Digital Proposal Creator